Pioglitazone Reduces Oxidative Stress in Kidney Against High Sucrose Diet-Induced Metabolic Syndrome in Rats
Abstract
Aim: The metabolic syndrome
(MS) is an important risk factor for the development of chronic kidney disease.
Thiazolidinediones (TZDs) provide renovascular protection, probably in the MS.
However, reports about the effect of pioglitazone on renal oxidative stress in
high sucrose diet-induced MS remains to be determined. The aim of this study
was to assess the effects of pioglitazone on oxidative stress markers in kidney
tissues of MS rats.
Material
and Method:
Male Wistar rats (200-250g in weight) were used in present study. They were
divided as control (Con) group, MS group (receiving 935 mM sucrose in drinking
water) and pioglitazone treated MS group (MSP) received pioglitazone treatment
(30 mg/kg/day, via gavage) for two weeks at the end of the 18th
weeks of MS group. Aspartate aminotransferase (AST), lactate dehydrogenase
(LDH), total oxidant status (TOS), and total antioxidant status (TAS) levels
were measured using commercial kits. Thiobarbituric acid reactive substances
(TBARS), reduced glutathione (GSH), urea, uric acid and
creatinine were measured. Thioredoxin 1 (TRX1) level was measured in cytosol
and membrane tissues by western blot. TRX1 activity was measured in cytosol and
membrane tissues using commercial kit.
Results: Compared with control
rats, the sucrose-fed rats exhibited several characteristics of MS, including
central obesity, insulin resistance, hyperinsulinemia, and
hypertriglyceridemia. Furthermore, changed levels of AST, LDH, TOS, TAS, TBARS,
GSH, urea, uric acid, creatinine and TRX1 activity and protein levels in the MS
group were reversed to control levels by administration of pioglitazone.
Conclusion: Pioglitazone reduced
the elevated oxidative stress in kidney of MS rats.
Keywords
References
- 1. Masson W, Epstein T, Huerín M, Lobo LM, Molinero G, Angel A et al. Cardiovascular risk stratification in patients with metabolic syndrome Without diabetes or cardiovascular disease: Usefulness of metabolic syndrome severity score. High Blood Press Cardiovasc Prev. 2017; 24(3):297-303.
- 2. Huh JH, Yadav D, Kim JS, Son JW, Choi E, Kim SH et al. An association of metabolic syndrome and chronic kidney disease from a 10-year prospective cohort study. Metabolism 2017; 67:54–61.
- 3. Panwar B, Hanks LJ, Tanner RM, Muntner P, Kramer H, McClellan WM et al. Obesity, metabolic health, and the risk of end-stage renal disease. Kidney Int 2015; 87:1216–22.
- 4. Prasad GVR. Metabolic syndrome and chronic kidney disease: current status and future directions. World J Nephrol 2014; 3:210–9.
- 5. Kurella M, Lo JC, Chertow GM. Metabolic syndrome andthe risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005; 16:2134–40.
- 6. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240:889-95.
- 7. Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clinl Invest. 1997; 100:1863.
- 8. Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF et al. Pioglitazone induces in vivo adipocyte differentiation in the obese zucker fa/fa rat. Diabetes 1997; 46:1393-9.
Details
Primary Language
English
Subjects
-
Journal Section
Research Article
Authors
Publication Date
December 1, 2018
Submission Date
May 15, 2018
Acceptance Date
-
Published in Issue
Year 2018 Volume: 8 Number: 3